Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Julien EDELINE, Professor

    Principal Investigator

    Centre Eugène Marquis

  • Laure Monard

    Study Director

    UNICANCER